Improving Care in Eosinophil-Associated Diseases: A Charter.
Eosinophil-associated diseases
Eosinophilic immune dysfunction (EID)
Healthcare professional (HCP) education
Multidisciplinary teams (MDTs)
Patient education
Patient rights
Timely diagnosis
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
16
11
2021
accepted:
02
03
2022
pubmed:
1
5
2022
medline:
25
5
2022
entrez:
30
4
2022
Statut:
ppublish
Résumé
Eosinophil-associated diseases (EADs) are a range of heterogeneous conditions in which eosinophils are believed to play a critical pathological role. EADs include common illnesses such as eosinophilic asthma and chronic rhinosinusitis and rare conditions such as hypereosinophilic syndromes (HES) and eosinophilic gastrointestinal disorders (EGIDs). EADs are associated with substantial burdens for the patient, including chronic, debilitating symptoms, increased financial burden, decreased health-related quality of life, and the need for repeated visits to multiple different healthcare professionals (HCPs), emergency departments, and/or hospitals. Poor EAD recognition by HCPs often contributes to delayed diagnoses, which further delays patient access to appropriate care and effective treatments, contributing to poor health outcomes. The objective of this charter is to outline key patient rights and expectations with respect to the management of their condition(s) and to set forth an ambitious action plan to improve health outcomes for patients with EADs: (1) people with EADs, their caretakers, HCPs, and the public must have greater awareness and education about EADs; (2) people with EADs must receive a timely, accurate diagnosis; (3) all people with EADs must have access to an appropriate multidisciplinary team, when necessary; and (4) people with EADs must have access to safe and effective treatment options without unnecessary regulatory delays. The principles described in this charter demonstrate the core elements of quality care that people with EADs must receive, and they represent clear steps by which to reduce patient and caregiver burden and improve patient outcomes. We urge HCPs, healthcare systems, and policymakers worldwide to swiftly adopt these principles to ensure patients with EADs have an accurate diagnosis in a timely manner and access to high-level care and treatment in an appropriate setting.
Identifiants
pubmed: 35489014
doi: 10.1007/s12325-022-02110-8
pii: 10.1007/s12325-022-02110-8
pmc: PMC9055373
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
2323-2341Informations de copyright
© 2022. The Author(s).
Références
Sastre B, Rodrigo-Munoz JM, Garcia-Sanchez DA, Canas JA, Del Pozo V. Eosinophils: old players in a new game. J Investig Allergol Clin Immunol. 2018;28(5):289–304.
pubmed: 30059011
doi: 10.18176/jiaci.0295
Cogan E, Roufosse F. Clinical management of the hypereosinophilic syndromes. Expert Rev Hematol. 2012;5(3):275–89 (quiz 290).
pubmed: 22780208
doi: 10.1586/ehm.12.14
Simon D, Simon H-U. Eosinophils and skin diseases. In: Lee J, Rosenberg H, editors. Eosinophils in health and disease. 1st ed. London: Academic Press; 2012. p. 442–7.
Gonsalves N. Eosinophilic gastrointestinal disorders. Clin Rev Allergy Immunol. 2019;57(2):272–85.
pubmed: 30903439
doi: 10.1007/s12016-019-08732-1
Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease. Annu Rev Pathol. 2020;15:179–209.
pubmed: 31977298
pmcid: 7604902
doi: 10.1146/annurev-pathmechdis-012419-032756
Jacobsen EA, Jackson DJ, Heffler E, Mathur SK, Bredenoord AJ, Pavord ID, et al. Eosinophil knockout humans: uncovering the role of eosinophils through eosinophil-directed biological therapies. Annu Rev Immunol. 2021;39:719–57.
pubmed: 33646859
pmcid: 8317994
doi: 10.1146/annurev-immunol-093019-125918
Rodrigo-Munoz JM, Gil-Martinez M, Sastre B, Del Pozo V. Emerging evidence for pleiotropism of eosinophils. Int J Mol Sci. 2021;22(13):7075.
pubmed: 34209213
pmcid: 8269185
doi: 10.3390/ijms22137075
Jackson DJ, Busby J, Pfeffer PE, Menzies-Gow A, Brown T, Gore R, et al. Characterisation of patients with severe asthma in the UK severe asthma registry in the biologic era. Thorax. 2021;76(3):220–7.
pubmed: 33298582
doi: 10.1136/thoraxjnl-2020-215168
Heaney LG, Perez de Llano L, Al-Ahmad M, Backer V, Busby J, Canonica GW, et al. Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort. Chest. 2021;160(3):814–30.
pubmed: 33887242
doi: 10.1016/j.chest.2021.04.013
Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol. 1951;27(2):277–301.
pubmed: 14819261
pmcid: 1937314
Noth I, Strek ME, Leff AR. Churg-strauss syndrome. Lancet. 2003;361(9357):587–94.
pubmed: 12598156
doi: 10.1016/S0140-6736(03)12518-4
Hiremath G, Kodroff E, Strobel MJ, Scott M, Book W, Reidy C, et al. Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care. Clin Res Hepatol Gastroenterol. 2018;42(5):483–93.
pubmed: 29615329
pmcid: 6167209
doi: 10.1016/j.clinre.2018.03.003
Bell CF, Blauer-Peterson C, Mao J. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States. J Manag Care Spec Pharm. 2021;27:1249–59.
pubmed: 34165321
Jakes RW, Kwon N, Nordstrom B, Goulding R, Fahrbach K, Tarpey J, et al. Burden of illness associated with eosinophilic granulomatosis with polyangiitis: a systematic literature review and meta-analysis. Clin Rheumatol. 2021;40:4829–36.
pubmed: 34159493
pmcid: 8599408
doi: 10.1007/s10067-021-05783-8
Chen S, Zhou A, Emmanuel B, Garcia D, Rosta E. Systematic literature review of humanistic and economic burdens of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1913–26.
pubmed: 32851882
doi: 10.1080/03007995.2020.1815683
Jensen ET, Aceves SS, Bonis PA, Bray K, Book W, Chehade M, et al. High patient disease burden in a cross-sectional, multicenter contact registry study of eosinophilic gastrointestinal diseases. J Pediatr Gastroenterol Nutr. 2020;71(4):524–9.
pubmed: 32541201
pmcid: 7574400
doi: 10.1097/MPG.0000000000002817
Haughney J, Winders TA, Holmes S, Chanez P, Saul H, Menzies-Gow A, et al. Global quality standard for identification and management of severe asthma. Adv Ther. 2020;37(9):3645–59.
pubmed: 32725419
pmcid: 7444397
doi: 10.1007/s12325-020-01450-7
Bousquet J, Bachert C, Canonica GW, Casale TB, Cruz AA, Lockey RJ, et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol. 2009;124(3):428–33.
pubmed: 19660803
doi: 10.1016/j.jaci.2009.06.027
Chehade M, Kamboj AP, Atkins D, Gehman LT. Diagnostic delay in patients with eosinophilic gastritis and/or duodenitis: A population-based study. J Allergy Clin Immunol Pract. 2021;9(5):2050-2059 e2020.
pubmed: 33440255
doi: 10.1016/j.jaip.2020.12.054
Groh M, Pagnoux C, Baldini C, Bel E, Bottero P, Cottin V, et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) consensus task force recommendations for evaluation and management. Eur J Intern Med. 2015;26(7):545–53.
pubmed: 25971154
doi: 10.1016/j.ejim.2015.04.022
Steinbach EC, Hernandez M, Dellon ES. Eosinophilic esophagitis and the eosinophilic gastrointestinal diseases: approach to diagnosis and management. J Allergy Clin Immunol Pract. 2018;6(5):1483–95.
pubmed: 30201096
pmcid: 6134874
doi: 10.1016/j.jaip.2018.06.012
Hannane A, Misane L, Devouassoux G, Colin C, Letrilliart L. Asthma patients’ perception on their care pathway: a qualitative study. NPJ Prim Care Respir Med. 2019;29(1):9.
pubmed: 30940806
pmcid: 6445145
doi: 10.1038/s41533-019-0121-2
Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204.
pubmed: 30214247
pmcid: 6121746
doi: 10.2147/JAA.S176026
Al Efraij K, Johnson KM, Wiebe D, Sadatsafavi M, Fitz Gerald JM. A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. J Asthma. 2019;56(12):1334–46.
pubmed: 30513226
doi: 10.1080/02770903.2018.1539100
Voorham J, Xu X, Price DB, Golam S, Davis J, Zhi Jie Ling J, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74(2):273–83.
pubmed: 29987879
doi: 10.1111/all.13556
Bleecker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276–93.
pubmed: 31525297
pmcid: 6999108
doi: 10.1164/rccm.201904-0903SO
Cataldo D, Louis R, Michils A, Peché R, Pilette C, Schleich F, et al. Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. J Asthma. 2021;58(4):448–58.
pubmed: 31928102
doi: 10.1080/02770903.2019.1705335
Menzies-Gow A, Canonica GW, Winders TA, Correia de Sousa J, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Adv Ther. 2018;35(10):1485–96.
pubmed: 30182174
pmcid: 6182619
doi: 10.1007/s12325-018-0777-y
Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, 2021 report; 2021. https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf .
Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757–65.
pubmed: 31866436
doi: 10.1016/j.jaci.2019.12.006
Upham JW, Le Lievre C, Jackson DJ, Masoli M, Wechsler ME, Price DB, et al. Defining a severe asthma super-responder: findings from a Delphi process. J Allergy Clin Immunol Pract. 2021;9(11):3997–4004.
pubmed: 34271216
doi: 10.1016/j.jaip.2021.06.041
Thompson WG. The road to rome. Gastroenterology. 2006;130(5):1552–6.
pubmed: 16678568
doi: 10.1053/j.gastro.2006.03.011
Schmulson MJ, Drossman DA. What is new in Rome IV. J Neurogastroenterol Motil. 2017;23(2):151–63.
pubmed: 28274109
pmcid: 5383110
doi: 10.5056/jnm16214
Abassa KK, Lin XY, Xuan JY, Zhou HX, Guo YW. Diagnosis of eosinophilic gastroenteritis is easily missed. World J Gastroenterol. 2017;23(19):3556–64.
pubmed: 28596692
pmcid: 5442092
doi: 10.3748/wjg.v23.i19.3556
Mouthon L, Dunogue B, Guillevin L. Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg–Strauss syndrome). J Autoimmun. 2014;48–49:99–103.
pubmed: 24530234
doi: 10.1016/j.jaut.2014.01.018
Jensen ET, Martin CF, Kappelman MD, Dellon ES. Prevalence of eosinophilic gastritis, gastroenteritis, and colitis: estimates from a national administrative database. J Pediatr Gastroenterol Nutr. 2016;62(1):36–42.
pubmed: 25988554
pmcid: 4654708
doi: 10.1097/MPG.0000000000000865
James C, Assa’ad A. The global face of eosinophilic esophagitis: advocacy and research groups. Clin Rev Allergy Immunol. 2018;55(1):99–105.
pubmed: 29730731
doi: 10.1007/s12016-018-8683-2
Sauer BG, West A, McGowan EC. Multidisciplinary eosinophilic esophagitis care: a model for comprehensive patient-centered care through shared decision making between gastroenterology, allergy, and nutrition. Clin Gastroenterol Hepatol. 2021;19:2226–9.
pubmed: 34280551
doi: 10.1016/j.cgh.2021.07.025
Merkel PA, Manion M, Gopal-Srivastava R, Groft S, Jinnah HA, Robertson D, et al. The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis. 2016;11(1):66.
pubmed: 27194034
pmcid: 4870759
doi: 10.1186/s13023-016-0445-8
Aceves S, Collins MH, Rothenberg ME, Furuta GT, Gonsalves N, Consortium of Eosinophilic Gastrointestinal Disease Researchers. Advancing patient care through the consortium of eosinophilic gastrointestinal disease researchers (CEGIR). J Allergy Clin Immunol. 2020;145(1):28–37.
pubmed: 31758958
doi: 10.1016/j.jaci.2019.11.012
Shaheen NJ, Mukkada V, Eichinger CS, Schofield H, Todorova L, Falk GW. Natural history of eosinophilic esophagitis: a systematic review of epidemiology and disease course. Dis Esophagus. 2018;31(8): doy015.
pmcid: 6102800
doi: 10.1093/dote/doy015
Ryan D, Heatley H, Heaney LG, Jackson DJ, Pfeffer PE, Busby J, et al. Potential severe asthma hidden in UK primary care. J Allergy Clin Immunol Pract. 2021;9(4):1612-1623 e1619.
pubmed: 33309935
doi: 10.1016/j.jaip.2020.11.053
Kliewer KL, Cassin AM, Venter C. Dietary therapy for eosinophilic esophagitis: elimination and reintroduction. Clin Rev Allergy Immunol. 2018;55(1):70–87.
pubmed: 29238902
doi: 10.1007/s12016-017-8660-1
Busse WW, Kraft M, Rabe KF, Deniz Y, Rowe P, Ruddy M, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021;2003393 (Online ahead of print).
Taberna M, Gil Moncayo F, Jane-Salas E, Antonio M, Arribas L, Vilajosana E, et al. The multidisciplinary team (MDT) approach and quality of care. Front Oncol. 2020;10:85.
pubmed: 32266126
pmcid: 7100151
doi: 10.3389/fonc.2020.00085
APFED. Specialist finder 2021. https://apfed.org/find-support-treatment/specialist-finder/ .
EOS_Network. Find a doctor 2021. https://www.eosnetwork.org/find-a-doctor .
Cushen B, Menzies-Gow A. Benralizumab: an updated treatment of eosinophilic asthma. Expert Rev Respir Med. 2020;14(5):435–44.
pubmed: 32133878
doi: 10.1080/17476348.2020.1739526
Hare N, Bansal P, Bajowala SS, Abramson SL, Chervinskiy S, Corriel R, et al. Work group report: Covid-19: unmasking telemedicine. J Allergy Clin Immunol Pract. 2020;8(8):2461-2473 e2463.
pubmed: 32603900
pmcid: 7320693
doi: 10.1016/j.jaip.2020.06.038
Chiesa Fuxench ZC, Block JK, Boguniewicz M, Boyle J, Fonacier L, Gelfand JM, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Investig Dermatol. 2019;139(3):583–90.
pubmed: 30389491
doi: 10.1016/j.jid.2018.08.028
Persson MSM, Harman KE, Vinogradova Y, Langan SM, Hippisley-Cox J, Thomas KS, et al. Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population-based cohort study. Br J Dermatol. 2021;184(1):68–77.
pubmed: 32147814
doi: 10.1111/bjd.19022
Vogelmeier CF, Chair A, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2021 report; 2021.
Fricke J, Avila G, Keller T, Weller K, Lau S, Maurer M, et al. Prevalence of chronic urticaria in children and adults across the globe: systematic review with meta-analysis. Allergy. 2020;75(2):423–32.
pubmed: 31494963
doi: 10.1111/all.14037
Limketkai BN, Shah SC, Hirano I, Bellaguarda E, Colombel JF. Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis. Gut. 2019;68(12):2152–60.
pubmed: 30923072
doi: 10.1136/gutjnl-2018-318074
Dellon ES, Jensen ET, Martin CF, Shaheen NJ, Kappelman MD. Prevalence of eosinophilic esophagitis in the United States. Clin Gastroenterol Hepatol. 2014;12(4):589–96.
pubmed: 24035773
doi: 10.1016/j.cgh.2013.09.008
Suzuki Y, Suda T. Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management. Allergol Int. 2019;68(4):413–9.
pubmed: 31253537
doi: 10.1016/j.alit.2019.05.006
Requena G, Logie J, Gibbons DC, Steinfeld J, Van Dyke MK. The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom. Immun Inflamm Dis. 2021;9:1447–51.
pubmed: 34293251
pmcid: 8589407
doi: 10.1002/iid3.495
Khan A, Vandeplas G, Huynh TMT, Joish VN, Mannent L, Tomassen P, et al. The global allergy and asthma european network (galen) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32–42.
pubmed: 29911211
doi: 10.4193/Rhin17.255